H
COAG
HEMAB THERAPEUTICS HOLDINGS
48.02
+0.71+1.50%Opening11:58 07/27 EDT
OPEN/PREV CLOSE50.85/50.39
TODAY RANGE45.93-50.85
VOL125.16K
MARKET CAP2.15B
52 WEEK RANGE23.00-52.15
AVG VOL (3M)363.74K
% TURNOVER0.27%
TURNOVER--
P/E (TTM)-89.4624
% RANGE9.76%
EPS(TTM)-0.5134
P/E(FORWARD)-16.9483
P/B12.56
BVPS3.656
DIVIDEND--
P/S--
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP1.91B
SHARES OUTSTANDING46.71M
NEXT EARNINGS--
FREE FLOAT41.67M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Seeking Alpha·5d ago
Biotech stocks lead healthcare's overbought list as earnings picks up
NASDAQ·07/21 07:41
Biotech Stocks At 52-Week Highs - XNCR, COAG, MNPR, SOPH, ACRS
NASDAQ·07/15 11:08
Hemab Presents Sutacimig Data; Wedbush Rates Outperform, $55 Target
Seeking Alpha·07/15 07:52
Hemab Therapeutics: A Cash-Rich Coagulation Franchise With Multiple Clinical Catalysts
TipRanks·07/14 11:50
Hemab Therapeutics presents sutacimig data at ISTH Congress
NASDAQ·07/14 08:03
Biotech Stocks At 52-Week Highs - COAG, ALMR, PGNY, TXG, VMD
Seeking Alpha·07/14 07:55
Mega-Deals Push H1 2026 U.S. Equity Issuance Into Orbit
TipRanks·07/13 18:50
Analysts Are Bullish on Top NA Stocks: HawkEye 360, Inc. (HAWK), SpaceX (SPCX)
Dow Jones·07/13 18:48
Hemab Therapeutics Hldgs Is Maintained at Buy by Jefferies
Benzinga·07/13 18:39
Jefferies Maintains Buy on Hemab Therapeutics Hldgs, Raises Price Target to $47
Benzinga·07/13 17:47
Hemab Advances Bleeding Disorder Pipeline
Dow Jones·07/13 13:28
Hemab Therapeutics Hldgs Price Target Raised to $55.00/Share From $42.00 by Wedbush